NASDAQ · Biotechnology

GOVX (GOVX) Stock

$0.70 -3.92% NASDAQ: GOVX Healthcare

Valuation

MetricValue
Price$0.70
Market Cap$669203
P/E Ratio-0.06
P/B Ratio0.28
P/S Ratio1.51
EPS (TTM)$-22.40
52-Week High$24.50
52-Week Low$0.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-525.00%
ROA-350.00%
ROCE-733.33%
Gross Margin-1100.00%
Operating Margin-1100.00%
Net Margin-25.07%
Debt/Equity0.80
Current Ratio2.74

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$4.0M$2.0M
Operating Profit$-19.0M$-14.0M$-27.0M$-25.0M$-22.0M
Net Profit$-19.0M$-14.0M$-26.0M$-25.0M$-21.0M
EPS$-182.50$-138.00$-255.50$-120.50$-22.40
Op Margin-4862.7%-17207.5%—-635.8%-869.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$12.0M$31.0M$9.0M$8.0M$6.0M
Total Liabilities$7.0M$5.0M$4.0M$3.0M$3.0M
Cash$11.0M$28.0M$6.0M$6.0M$3.0M
Borrowings$0$0$0$0$1.0M

Latest News

GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy NewMediaWire · Jul 21, 2026 GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness NewMediaWire · Jul 1, 2026 GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift Simply Wall St. · Jun 27, 2026 GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers NewMediaWire · Jun 17, 2026 GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Zacks · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-19.0M$-25.0M$-25.0M$-21.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$3.0M$8.0M$0$2.0M$0
Net Cash Flow$2.0M$16.0M$-21.0M$-1.0M$-2.0M
Free Cash Flow$-11.0M$-19.0M$-25.0M$-25.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.43
EV / EBITDA—
FCF Yield-1483.77%
Quick Ratio1.06
Interest Coverage—
Return 1Y-94.14%
Return 3Y-99.54%
Return 5Y-99.94%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ADTX $0.01 -77.22% -0.01 $318 0.00%
AIMD $1.49 -3.87% -0.43 $10.97M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
APLMApollomics, Inc. $18.76 +2.99% -2.41 $20.69M 0.00%

About GOVX

GOVX is led by CEO David Alan Dodd, employs 17 people, headquartered in US, publicly traded since 2020.

GOVX stock trades at $0.70 with a market capitalization of $669203. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.28, price-to-sales of 1.51. Over the past 52 weeks the stock has ranged between $0.70 and $24.50, and currently trades 97.1% below its 52-week high.

On profitability, GOVX generates a return on equity (ROE) of -525.00%, return on capital employed of -733.33%, an operating margin of -1100.00%, a net profit margin of -25.07%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides